Indian drugmaker Claris Injectibles, a subsidiary of Claris Lifesciences Limited, earned Food and Drug Administration approval for its tobramycin injectable medication.
Tobramycin is an anti-infective used to treat serious bacterial infections, including meningitis and infections of the blood, abdomen, lungs, bone and urinary tract.
Claris currently has 14 drug approvals, with 24 pending. The company expects more market approvals later this year.
More articles on supply chain:
4 latest FDA approvals
Pfizer agrees to acknowledge addiction risks in opioid marketing
FDA approves safety device that prevents needle sticks